Skip to content
#reinforcement learning Dataset Open access

RegTrace v1 — FDA Regulatory Trajectory Dataset for Reinforcement Learning

Sep 2026 · Zenodo (CERN European Organization for Nuclear Research)

Abstract

This page on Zenodo hosts a free sample only (50 trajectories) — not the full dataset. The complete RegTrace v1 dataset — 29,395 trajectories, 457 SFT traces with full CRL letter text, and 795 forecasting records — is available at sentineldata.com.ua/dataset/regtrace-v1. This sample is a true, unmodified subset of the full dataset (the first 50 rich episodes) and contains: regtrace_v1_sample.parquet — 50 rows × 14 columns, flat tabular view with deficiency counts and outcomes regtrace_v1_sample_episodes.jsonl — 50 full RL episodes with decision-point turns, rewards, and CRL observations Dataset Architecture & Specifications RegTrace v1 is a fully real, non-synthetic dataset of FDA drug-application regulatory trajectories, built entirely from public openFDA sources (Drugs@FDA bulk data, the CRL Transparency archive, and the openFDA API) and restructured into reinforcement-learning episodes with verifiable rewards. There are no simulated patients, no modeled physiology, and no estimated parameters: every application number, CRL letter, and outcome is a real government record, and 100% of the underlying source counts were confirmed by direct download in the current build session (full provenance in the included audit file, regtrace_v1_audit.parquet). Metric Value Total Trajectories 29,395 (336 rich / 459 semi-rich / 28,600 thin skeletons) CRL Letters (full text, SFT-ready) 457 traces, 10K+ characters each RL Decision Points 4,561 across DP1–DP4, each with a verifiable reward Data Schema 4 Parquet files + 2 JSONL files, deterministic pipeline (script included), no random seed needed Trajectory Tiers & RL Decision Points Rich (336, 1.1%): full CRL-matched trajectories with deficiency-category breakdown across all four decision points. Semi-rich (459, 1.6%): CRL-linked trajectories with partial event coverage. Thin skeletons (28,600, 97.3%): application-level event timelines (submission through final action) with no CRL deficiency detail — built for large-scale trajectory-shape modeling, not CRL-text prediction. Each rich/semi-rich trajectory carries up to four decision points with a verifiable ground-truth reward: DP1 — predict_outcome_AP_or_TA (3,289 instances): approval vs. tentative approval before FDA action. DP2 — predict_deficiency_categories (457 instances): CRL deficiency categories. DP3 — predict_time_to_resubmission_days (358 instances): days to resubmission. DP4 — predict_final_outcome (457 instances): approval / withdrawal / pending. Validation Metrics Parameter Provenance: 100% of source counts VERIFIED by direct download and count-confirmation in the current build session — 0% estimated, 0% unsourced. Validation Gates: 6 of 7 automated gates PASS; G2 (reward completeness) is PARTIAL — 121 of 4,561 decision-point rewards are pending because the underlying CRL is too recent to have a resolved resubmission or final action. Deficiency-Category Labeling: spot-checked at 100% accuracy on a 20-CRL / 333-item audit sample; treat as high-confidence heuristic labeling, not independently double-annotated across the full 5,489-item set. Known Limitations 121 of 4,561 decision-point rewards are pending (recent CRLs without a resolved subsequent action yet). The semi-rich count (459) came in below an earlier ~695 estimate because SubmissionClassCodeID wasn't available in the bulk Drugs@FDA tables; the openFDA API's submission_class_code field was used instead. 122 of 458 CRL letters could not be matched to a Drugs@FDA bulk-dump application (recent or CBER applications) and are included as CRL-only rich trajectories (97 additional). 1 CRL letter has no parseable date, so the SFT set contains 457 traces against 458 total CRL letters. Scope is FDA only — no EMA, PMDA, or other regulators. openFDA is a living, regularly-updated source; this is a frozen snapshot (source pulls dated 2026-08-26 to 2026-09-03) — re-running the included deterministic pipeline against a fresh openFDA pull will produce different, updated counts. Total on-disk size is modest (~8.2 MB). The value here is in structure and curation — RL episode packaging, verified rewards, deficiency taxonomy — not in raw data volume; the underlying openFDA data itself is freely downloadable by anyone. License All underlying data is US government public domain (17 USC 105). No copyright restrictions apply to the source data. Dataset packaging, structuring, and documentation by Sentinel Data.

View source

Similar papers

#machine learning Review Open access Oct 2014

Software development in startup companies: A systematic mapping study

The results indicate that software engineering work practices are chosen opportunistically, adapted and configured to provide value under the constrains imposed by the startup context.

Nicolò Paternoster, Carmine Giardino, M. Unterkalmsteiner et al. · 394 citations · ⚡54
#machine learning Review Open access Jun 2014

Why Early-Stage Software Startups Fail: A Behavioral Framework

This state-of-practice investigation was performed using a literature review followed by a multiple-case study approach and presents how inconsistency between managerial strategies and execution can lead to failure by means of a behavioral framework.

Carmine Giardino, Xiaofeng Wang, P. Abrahamsson · 175 citations · ⚡19
#machine learning Review Open access Oct 2016

“Failures” to be celebrated: an analysis of major pivots of software startups

This study conducts a case survey study based on the secondary data of the major pivots happened in 49 software startups, and demonstrates that customer need pivot is the most common among all pivot types.

Sohaib Shahid Bajwa, Xiaofeng Wang, Anh Nguyen-Duc et al. · 127 citations · ⚡15
#machine learning Review Open access May 2016

Key Challenges in Software Startups Across Life Cycle Stages

It is found that what perceived as biggest challenges by software startups do vary across different life cycle stages, even though its significance decreases when the learning focuses of the startups move from problem to solution and their products mature.

Xiaofeng Wang, Henry Edison, Sohaib Shahid Bajwa et al. · 62 citations · ⚡6

Related blog posts

MIT News · Artificial Intelligence Oct 7, 2026

Discovering the value of humanistic inquiry

Students in MIT’s Concourse program delve deeply into the human condition, debate challenging questions, and learn to develop judgment about issues that can’t be quantified.

Microsoft Research Blog Oct 7, 2026

Agent Lightning v1.0: A 3,500-Line Lightweight Agentic RL Framework for Training Agents with Real Harnesses

Training AI agents with reinforcement learning can be challenging because their tools, context, and decision-making are managed by complex frameworks. Agent Lightning connects existing agents to RL training, making it easier to improve them without rebuilding them. The post Agent Lightning v1.0: A 3,500-Line Lightweight Agentic RL Framework for Training Agents with Real Harnesses appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.